BioCentury
ARTICLE | Clinical News

V-5 Immunitor: Phase II data

November 15, 2010 8:00 AM UTC

An open-label, Ukrainian Phase II trial in 20 chronic HCV patients co-infected with HIV and TB showed that once-daily oral V5 significantly reduced serum ALT levels from 1.72 µmol/mL/hour at baseline ...